Back to results
US 10,286,091 B2Granted
Dendri-TAC and their use as theranostics
AssigneesUniversite D'Avignon Et Des Pays Du Vaucluse, Centre National De La Recherche Scientifique
InventorsStéphane Desgranges, Wlodzimierz Urbach, Lucie Somaglino, Nicolas Taulier, Christiane Pepin
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel amphiphilic dendrimers, hereafter denoted Dendri-TAC. The present invention also relates to perfluorocarbon nanoemulsions stabilized by these amphiphilic dendrimers and their uses for in vivo diagnostic and/or for therapy, notably as theranostic tools, for detection and/or treatment of cancer.
Claims25
An amphiphilic dendrimer of generation n comprising:
- an hydrophobic central core of valence 2 or 3;
- generation chains attached to the central core and branching around the core;
- and
- an hydrophilic terminal group at the end of each generation chain;
- wherein,
- n is an integer from 0 to 12;
- the hydrophilic terminal group comprises:
- a cyclodextrin residue,
- a polyethylene glycol (PEG) residue,
- a peptide residue,
- a tris(hydroxymethyl)aminoethane (Tris), or
- a 2-amino-2-methylpropane-1,3-diol;
- the central core being a group of formula (Ia) or (Ib):
- wherein:
- W is RF or a group selected from the group consisting of W0, W1, W2 and W3:
- RF is a C4-C10 perfluoroalkyl or a C1-C24 alkyl group,
- RH is a C1-C24 alkyl group,
- p is 0, 1, 2, 3 or 4;
- q is 0, 1, 2, 3 or 4;
- L is a linear or branched C1-C12 alkylene group, optionally interrupted by one or more —O—, —S—,
- Z is C(═O)NH or NHC(═O),
- R is a C1-C6 alkyl group, and
- e is at each occurrence independently 0, 1, 2, 3 or 4.
20 more elements
Dependencies are inferred from the claim text.